Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hervé Marchais is active.

Publication


Featured researches published by Hervé Marchais.


Analyst | 2005

Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy

Igor Chourpa; Laurence Douziech-Eyrolles; Lazare Ngaboni-Okassa; Jean-François Fouquenet; S. Cohen-Jonathan; Martin Soucé; Hervé Marchais; Pierre Dubois

The chemical and structural properties of ferrite-based nanoparticles, precursors for magnetic drug targeting, have been studied by Raman confocal multispectral imaging. The nanoparticles were synthesised as aqueous magnetic fluids by co-precipitation of ferrous and ferric salts. Dehydrated particles corresponding to co-precipitation (CP) and oxidation (OX) steps of the magnetic fluid preparation have been compared in order to establish oxidation-related Raman features. These are discussed in correlation with the spectra of bulk iron oxides (magnetite, maghemite and hematite) recorded under the same experimental conditions. Considering a risk of laser-induced conversion of magnetite into hematite, this reaction was studied as a function of laser power and exposure to oxygen. Under hematite-free conditions, the Raman data indicated that nanoparticles consisted of magnetite and maghemite, and no oxyhydroxide species were detected. The relative maghemite/magnetite spectral contributions were quantified via fitting of their characteristic bands with Lorentzian profiles. Another quality parameter, contamination of the samples with carbon-related species, was assessed via a broad Raman band at 1580 cm(-1). The optimised Raman parameters permitted assessment of the homogeneity and stability of the solid phase of prepared magnetic fluids using chemical imaging by Raman multispectral mapping. These data were statistically averaged over each image and over six independently prepared lots of each of the CP and OX nanoparticles. The reproducibility of oxidation rates of the particles was satisfactory: the maghemite spectral fraction varied from 27.8 +/- 3.6% for the CP to 43.5 +/- 5.6% for the OX samples. These values were used to speculate about the layered structure of isolated particles. Our data were in agreement with a model with maghemite core and magnetite nucleus. The overall oxidation state of the particles remained nearly unchanged for at least one month.


Nanotechnology | 2008

The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications

Katel Hervé; Laurence Douziech-Eyrolles; Emilie Munnier; S. Cohen-Jonathan; Martin Soucé; Hervé Marchais; P Limelette; Fabienne Warmont; Marie-Louise Saboungi; Pierre Dubois; Igor Chourpa

We report here the development of stable aqueous suspensions of biocompatible superparamagnetic iron oxide nanoparticles (SPIONs). These so-called ferrofluids are useful in a large spectrum of modern biomedical applications, including novel diagnostic tools and targeted therapeutics. In order to provide prolonged circulation times for the nanoparticles inxa0vivo, the initial iron oxide nanoparticles were coated with a biocompatible polymer poly(ethylene glycol) (PEG). To permit covalent bonding of PEG to the SPION surface, the latter was functionalized with a coupling agent, 3-aminopropyltrimethoxysilane (APS). This novel method of SPION PEGylation has been reproduced in numerous independent preparations. At each preparation step, particular attention was paid to determine the physico-chemical characteristics of the samples using a number of analytical techniques such as atomic absorption, Fourier transform infrared (FT-IR) spectroscopy and Raman spectroscopy, transmission electron microscopy (TEM), photon correlation spectroscopy (PCS, used for hydrodynamic diameter and zeta potential measurements) and magnetization measurements. The results confirm that aqueous suspensions of PEGylated SPIONs are stabilized by steric hindrance over a wide pH range between pH 4 and 10. Furthermore, the fact that the nanoparticle surface is nearly neutral is in agreement with immunological stealthiness expected for the future biomedical applications inxa0vivo.


International Journal of Pharmaceutics | 2008

Novel method of doxorubicin–SPION reversible association for magnetic drug targeting

Emilie Munnier; S. Cohen-Jonathan; Claude Linassier; Laurence Douziech-Eyrolles; Hervé Marchais; Martin Soucé; Katel Hervé; Pierre Dubois; Igor Chourpa

A new method of reversible association of doxorubicin (DOX) to superparamagnetic iron oxide nanoparticles (SPION) is developed for magnetically targeted chemotherapy. The efficacy of this approach is evaluated in terms of drug loading, delivery kinetics and cytotoxicity in vitro. Aqueous suspensions of SPION (ferrofluids) were prepared by coprecipitation of ferric and ferrous chlorides in alkaline medium followed by surface oxidation by ferric nitrate and surface treatment with citrate ions. The ferrofluids were loaded with DOX using a pre-formed DOX-Fe(2+) complex. The resulting drug loading was as high as 14% (w/w). This value exceeds the maximal loading known from literature up today. The release of DOX from the nanoparticles is strongly pH-dependent: at pH 7.4 the amount of drug released attains a plateau of approximately 85% after 1h, whereas at pH 4.0 the release is almost immediate. At both pH, the released drug is iron-free. The in vitro cytotoxicity of the DOX-loaded SPION on the MCF-7 breast cancer cell line is similar to that of DOX in solution or even higher, at low-drug concentrations. The present study demonstrates the potential of the novel method of pH-sensitive DOX-SPION association to design novel magnetic nanovectors for chemotherapy.


European Journal of Pharmaceutical Sciences | 2003

Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release

Hervé Marchais; Guillaume Cayzeele; Jean-Yves Legendre; Mohamed Skiba; Philippe Arnaud

The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resulting in different stressed capsules and carbamazepine (CBZ) was chosen as a drug model. In vitro dissolution studies were conducted using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS) was added in the dissolution medium at a concentration of 2% m/v both in SGF and SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved was reduced by increasing the degree of gelatin cross-linking. For unstressed hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for highly stressed hard gelatin capsules in the SGF. A similar effect was observed with SIF. In the case of moderately stressed hard gelatin capsules, addition of enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of enzyme in the dissolution medium did not increase the dissolution of CBZ from highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the medium did not allow the release of the CBZ both in SGF and in SIF. The results of this study demonstrate that the use of enzyme in the dissolution medium is justified for moderately cross-linked hard gelatin capsules. However, the action of a surfactant added in the medium containing enzyme remains unclear.


International Journal of Pharmaceutics | 2013

Use of experimental design methodology for the development of new magnetic siRNA nanovectors (MSN)

Stephanie David; Hervé Marchais; Katel Hervé-Aubert; Didier Bedin; Anne-Sophie Garin; Claude Hoinard; Igor Chourpa

Short interfering RNAs (siRNAs) can downregulate the synthesis of proteins and thus be used to treat certain diseases where the protein synthesis is upregulated, such as cancer. The challenge is to deliver siRNAs in the target cell as they are rapidly degraded by nucleases and have difficulties to cross the cellular membranes. Superparamagnetic iron oxide nanoparticles (SPIONs) are widely studied as platforms for smart biocompatible nanosystems which can be used for magnetic drug targeting and magnetic resonance imaging. The aim of this work was to combine siRNAs, SPIONs, and chitosan, to develop new magnetic siRNA nanovectors suitable for systemic administration. In a first time, the one factor at a time (OFAT) methodology was used to adjust different formulation parameters and to test the feasibility of such a formulation. In a second time, design of experiment (DOE) methodology was used to analyze the influence of these formulation parameters on the physicochemical characteristics hydrodynamic diameter (DH) and ζ-potential. Finally, four MSNs suitable for systemic administration could be identified using the OFAT method. The DOE method showed a significant effect of CR and [NaNO3] on the DH and a significant effect of MR and [siRNA] on the ζ-potential of the nanocarriers.


European Journal of Pharmaceutical Sciences | 2017

siRNA delivery system based on magnetic nanovectors: Characterization and stability evaluation

Mohammed Abdelrahman; Laurence Douziech Eyrolles; Suad Y. Alkarib; Katel Hervé-Aubert; Sanaa Ben Djemaa; Hervé Marchais; Igor Chourpa; Stephanie David

Abstract Gene therapy and particularly small interfering RNA (siRNA) is a promising therapeutic method for treatment of various human diseases, especially cancer. However the lack of an ideal delivery system limits its clinical applications. Effective anticancer drug development represents the key for translation of research advances into medicines. Previously we reported, the optimization of magnetic siRNA nanovectors (MSN) formulation based on superparamagnetic iron oxide nanoparticles (SPION) and chitosan for systemic administration. This work aimed at using rational design to further optimize and develop MSN. Therefore, formulated MSN were first purified, then their physical and chemical properties were studied mainly through capillary electrophoresis. 95% of siRNA was found enclosed within the purified MSN (pMSN). pMSN showed colloidal stability at pH 7.4, effective protection of siRNA against ribonuclease degradation up to 24 hours and few siRNA release (less than 10%) at pH 7.4. These findings push toward further evaluation studies in vitro and/or in vivo, indicating the appropriateness of pMSN for cancer theranostics. Graphical abstract Figure. No Caption available.


International Journal of Pharmaceutics | 2015

Modelling the response surface to predict the hydrodynamic diameters of theranostic magnetic siRNA nanovectors.

Stephanie David; Hervé Marchais; Didier Bedin; Igor Chourpa

Short interfering RNAs (siRNAs) appear to be a promising tool to treat various human diseases, such as cancer via the RNA interference (RNAi) mechanism. Since the systemic administration of siRNAs is limited by their capacity to attain the site of action, novel delivery systems are needed. Previously, we reported the formulation of magnetic siRNA nanovectors (MSN) using electrostatic assembly of the following components: (1) functionalized superparamagnetic iron oxide nanoparticles (SPIONs) able to act as agents for magnetic resonance imaging (MRI) and/or thermal therapy, (2) siRNAs as active molecules and (3) chitosan to protect siRNAs and to enhance their transfection efficacy. In this work, experimental design was used to further improve the formulation protocol and to optimize the component quantities. The aim was to obtain response surface plots that will help to optimize and predict the component quantities of the MSNs regarding their hydrodynamic diameter (DH). The influent parameters of the formulation process were determined using a Plackett-Burman design. The results show that the order of incorporation of the components is the most influent parameter on the DH of MSNs. A Box-Behnken design was used to optimize the component quantities. The model equations provided the parameters to obtain MSNs with DH smaller than 100 nm to allow their systemic administration.


International Journal of Pharmaceutics | 2017

Stealth magnetic nanocarriers of siRNA as platform for breast cancer theranostics

J. Bruniaux; S. Ben Djemaa; Katel Hervé-Aubert; Hervé Marchais; Igor Chourpa; Stephanie David

The endogenous mechanism of RNA interference is more and more used in research to obtain specific down-regulation of gene expression in diseases such as breast cancer. Currently, despite the new fields of study open up by RNA interference, the rapid degradation of siRNA by nucleases and their negative charges prevent them from crossing cell membranes. To overcome these limitations, superparamagnetic iron oxide nanoparticles (SPIONs) represent a promising alternative for nucleic acid delivery. Previously, we reported the magnetic siRNA nanovectors (MSN) formulation using electrostatic assembly of (1) SPIONs, also able to act as contrast agents for magnetic resonance imaging (MRI), (2) siRNA and (3) chitosan aiming at their protection and enhancing their transfection efficacy. However, these nanoparticles displayed low stability in biological suspensions and inefficient transfection of active siRNA. This work aimed at upgrading MSN to Stealth MSN (S-MSN) by adding a polyethylene glycol coating to ensure colloidal stability and stealth properties. Furthermore, another polymer (poly-L-arginine) was added for efficient siRNA transfection and the quantitative composition of the formulation was adapted for biological purposes. Results showed that S-MSN provide high siRNA complexation and protection against enzymatic degradation. Green fluorescent protein (GFP) specific down-regulation on MDA-MB231/GFP cells was comparable to that of commercially available reagents, without observable cytotoxicity. According to our works, S-MSN appears as an effective formulation for in vitro siRNA specific delivery.


European Journal of Pharmaceutics and Biopharmaceutics | 2007

Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods

Frederic Tewes; Emilie Munnier; B. Antoon; L. Ngaboni Okassa; S. Cohen-Jonathan; Hervé Marchais; Laurence Douziech-Eyrolles; Martin Soucé; Pierre Dubois; Igor Chourpa


International Journal of Nanomedicine | 2007

Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles.

Laurence Douziech-Eyrolles; Hervé Marchais; Katel Hervé; Emilie Munnier; Martin Soucé; Claude Linassier; Pierre Dubois; Igor Chourpa

Collaboration


Dive into the Hervé Marchais's collaboration.

Top Co-Authors

Avatar

Igor Chourpa

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Soucé

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Pierre Dubois

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

S. Cohen-Jonathan

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Emilie Munnier

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Katel Hervé

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Stephanie David

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Claude Linassier

François Rabelais University

View shared research outputs
Top Co-Authors

Avatar

Katel Hervé-Aubert

François Rabelais University

View shared research outputs
Researchain Logo
Decentralizing Knowledge